Clinical research and patient protection

Article information

J Korean Med Assoc. 2010;53(9):736-738

Publication date (electronic) : 2010 September 07

doi : https://doi.org/10.5124/jkma.2010.53.9.736

Moo Sang Lee, MD ^,

Chairman, Committee for Ethics and Judicial Review, KMA, Korea.

Chair Professor, Gachon University of Medicine and Science, Incheon, Korea. mooslee@gachon.ac.kr

Received 2010 July 04; Accepted 2010 July 17.

Abstract

Clinical trials are the flower of clinical research. Recently such clinical trials occur increasingly on a global scale. Korea is also one of the countries newly involved in global clinical trials, with resulting scientific, economic, industrial, and ethical implications. The sweeping and meticulous precautions must be introduced to these global clinical trials promoting patient protection through the public, national and international surveillance. These many guidelines in clinical trials are based on the Declaration of Helsinki of the World Medical Association (WMA). Fortunately, we were proud to be able to host the WMA 2008 meeting in Seoul, where the sixth edition of this declaration was announced. Thus, KMA insists that all clinical trials in Korea maintain strict standards and that all our member physicians follow the Declaration of Helsinki and be observers.

Keywords: Clinical trials; Patient protection; Globalization; Helsinki Declaration

Article information Continued

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.